Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant
- Conditions
- End-stage Renal Disease
- Interventions
- Biological: Rabbit Anti-thymocyte Immunoglobulin
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 115
- Registration Number
- NCT03099122
- Locations
- 🇨🇳
CHINA, China, China
Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT03070678
- Locations
- 🇫🇷
Investigational site 250001, Gières, France
PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 24
- Registration Number
- NCT03069963
- Locations
- 🇫🇷
Investigational Site Number 2500001, Gieres, France
Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 34
- Registration Number
- NCT03065816
- Locations
- 🇬🇧
Investigational site 826001, Merthyr Tydfil, United Kingdom
Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-02-24
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT03063580
- Locations
- 🇫🇷
Investigational Site Number 250001, Gieres, France
Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China
- Conditions
- Hyperphosphatemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 202
- Registration Number
- NCT03001011
- Locations
- 🇨🇳
Investigational Site Number 1560001, Guangzhou, China
🇨🇳Investigational Site Number 1560003, Beijing, China
🇨🇳Investigational Site Number 1560015, Changchun, China
Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia
- Conditions
- T-lymphoblastic Lymphoma/LeukaemiaT-cell Type Acute Leukemia-Precursor
- Interventions
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 14
- Registration Number
- NCT02999633
- Locations
- 🇺🇸
Investigational Site Number 8400001, Houston, Texas, United States
🇺🇸Investigational Site Number 8400002, Atlanta, Georgia, United States
🇫🇮Investigational Site Number 2460001, Helsinki, Finland
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 307
- Registration Number
- NCT02990338
- Locations
- 🇺🇸
BRCR Medical Center Inc. Site Number : 8400002, Plantation, Florida, United States
🇺🇸Dana Farber Site Number : 8400006, Boston, Massachusetts, United States
🇦🇺Investigational Site Number : 0360004, St Leonards, New South Wales, Australia
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 72
- Registration Number
- NCT02991469
- Locations
- 🇦🇷
Investigational Site Number : 0320004, San Miguel de Tucumán, Tucumán, Argentina
🇧🇬Investigational Site Number : 1000001, Plovdiv, Bulgaria
🇨🇦Investigational Site Number : 1240110, Calgary, Alberta, Canada
Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia
- Conditions
- HypercholesterolemiaAcute Coronary Syndrome
- Interventions
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 206
- Registration Number
- NCT02984982
- Locations
- 🇯🇵
Investigational Site Number 392008, Gifu-shi, Japan
🇯🇵Investigational Site Number 392022, Chiyoda-ku, Japan
🇯🇵Investigational Site Number 392039, Hiroshima-shi, Japan